LONDON, March 7,
2023 /PRNewswire/ -- Smith+Nephew (LSE:SN,
NYSE:SNN), the global medical technology company, today introduced
the UltraTRAC™ QUAD ACL Reconstruction Technique which consists of
the new QUADTRAC Quadriceps Tendon Harvest Guide System,
X-WING™ Graft Preparation System and family of ULTRABUTTON
Adjustable Fixation Devices. These technologies work together to
provide an innovative procedural solution, expanding Smith+Nephew's
ability to address surgeon graft preference.
The quadriceps tendon has been gaining popularity for use as a
graft option for ACL reconstruction due to the advantages it
offers.1-4 It is estimated that the number of US ACL
procedures will surpass 350,000 cases in 2023 and continue to grow
at a 5.7% CAGR.5
The QUADTRAC System is the first integrated guide-system for
minimally invasive quadriceps graft harvesting.6 The
system provides direct tendon visualization while enabling a
controlled and reproducible technique to harvest.7-9
With the launch of the QUADTRAC System, Smith+Nephew capitalizes on
the increasing use of the quad tendon graft, enabling graft
visualization and harvest optimization.
"The QUADTRAC System is a simple and efficient solution to allow
surgeons to harvest the quad tendon" said Dr. Scott Faucett, Centers for Advanced
Orthopaedics. "Quad tendon is often the best option for patients
undergoing ACL reconstruction and the guided cutting and tendon
visualization during the procedure that the QUADTRAC System offers
makes harvesting much easier. Plus, it enables surgeons to harvest
with and without a bone plug allowing a diverse use of the system
when using quad grafts in my practice."
Building on a 25-year legacy within the cortical suspensory
fixation segment, Smith+Nephew expands the family of ULTRABUTTON
Adjustable Fixation Devices with the release of three new
ULTRABUTTON products. With the launch of these new ULTRABUTTON
Devices, Smith+Nephew now offers specialized solutions that address
all grafts with all adjustable, all secure ACL fixation.
Dr. Cassandra Lee, University of California Davis commented, "With the
added ULTRABUTTON QUAD, BB and TIB Devices, Smith+Nephew now
provides me with a complete solution for all my ACL reconstruction
needs with quick graft preparation and minimal steps. Whether the
surgeon themselves or their surgical support staff performs graft
preparation, these devices can help improve operating room
efficiency."
The QUADTRAC Quadriceps Tendon Harvest Guide System and the
family of ULTRABUTTON Adjustable Fixation Devices that enable the
UltraTRAC QUAD ACL Reconstruction technique are commercially
available in the US and select countries across the world. They are
part of Smith+Nephew's expansive Reimagine reconstruction knee
ligament solutions portfolio. To learn more, please visit
https://www.smith-nephew.com/en/health-care-professionals/products/sports-medicine/quadtrac.
References
- Buerba RA, Boden SA, Lesniak B. Graft Selection in Contemporary
Anterior Cruciate Ligament Reconstruction. JAAOS: Global Research
and Reviews. 2021;5(10).
- Lund, Bent et al. "Is
Quadriceps Tendon a Better Graft Choice Than Patellar Tendon? A
Prospective Randomized Study." Arthroscopy 2014; 30(5):
593-598.
- Malinowski K, Paszkowski J, Mostowy M, Goralczyk A, Laprade RF,
Hermanowicz K. Quadriceps Tendon-Bone Full-Thickness Autograft:
Reproducible and Easy Harvesting Technique Using Simple Surgical
Tools. Arthroscopy Techniques. 2021;10(4).
- Dai W, Leng X, Wang J, Cheng J, Hu X, Ao Y. Quadriceps Tendon
Autograft Versus Bone-Patellar Tendon-Bone and Hamstring Tendon
Autografts for Anterior Cruciate Ligament Reconstruction: A
Systematic Review and Meta-analysis. Am J Sports Med.
2022;50(12):3425-3439.
- 2023 SmartTRAK US Knee Soft tissue fixation market report.
- Smith+Nephew 2022.Validation, QUADTRAC. Internal Report.
15011575 Rev A.
- Smith+Nephew 2022. QUADTRAC Marketing Claims. Internal Report.
15011572 Rev A.
- Smith+Nephew 2022.TRAC-Cutter Push-Pull Cut Force DV Protocol.
Internal Report. 15011552 Rev A.
- Smith+Nephew 2022.QUAD-Cutter Force to Cut Design Verification.
Internal Report. 15011559 Rev A.
About Smith+Nephew
Smith+Nephew is a portfolio medical
technology company focused on the repair, regeneration and
replacement of soft and hard tissue. We exist to restore people's
bodies and their self-belief by using technology to take the limits
off living. We call this purpose 'Life Unlimited'. Our 19,000
employees deliver this mission every day, making a difference to
patients' lives through the excellence of our product
portfolio, and the invention and application of new technologies
across our three global franchises of Orthopaedics, Sports
Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856,
we now operate in more than 100 countries, and generated annual
sales of $5.2 billion in 2022.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms 'Group' and 'Smith+Nephew' are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please
visit www.smith-nephew.com and follow us
on Twitter, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may
contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth
and trading margins, market trends and our product pipeline are
forward-looking statements. Phrases such as "aim", "plan",
"intend", "anticipate", "well-placed", "believe", "estimate",
"expect", "target", "consider" and similar expressions are
generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: risks
related to the impact of COVID-19, such as the depth and longevity
of its impact, government actions and other restrictive measures
taken in response, material delays and cancellations of elective
procedures, reduced procedure capacity at medical facilities,
restricted access for sales representatives to medical facilities,
or our ability to execute business continuity plans as a result of
COVID-19; economic and financial conditions in the markets we
serve, especially those affecting health care providers, payers and
customers (including, without limitation, as a result of COVID-19);
price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers
(including, without limitation, as a result of COVID-19);
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that
Smith+Nephew has filed with the U.S. Securities and Exchange
Commission under the U.S. Securities Exchange Act of 1934, as
amended, including Smith+Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith+Nephew as of the date of the statement. All written or oral
forward-looking statements attributable to Smith+Nephew are
qualified by this caution. Smith+Nephew does not undertake any
obligation to update or revise any forward-looking statement to
reflect any change in circumstances or in Smith+Nephew's
expectations.
™Trademark of Smith+Nephew. Certain marks
registered US Patent and Trademark Office.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/smithnephew-sports-medicine-advances-procedural-innovation-by-launching-the-quadtrac-quadriceps-tendon-harvest-guide-system-and-expanded-family-of-ultrabutton-adjustable-fixation-devices-for-acl-reconstruction-301762947.html
SOURCE Smith & Nephew plc